SCOPUS 정보 검색 플랫폼

Annals of Internal Medicine

Volumn 165, Issue 7, 2016, Pages 530-532

Euglycemic ketoacidosis caused by sodium-glucose cotransporter 2 inhibitors: A case report

(5) Bobart, Shane A a Gleason, Benjamin a Martinez, Nydia a Norris, Keith b Williams, Sandra F a

a DEPARTMENT OF COLORECTAL SURGERY (United States)

b UNIVERSITY OF CALIFORNIA (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; BICARBONATE; CANAGLIFLOZIN; CREATININE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; POTASSIUM; SODIUM CHLORIDE; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; ANION GAP; ARTERIAL PH; ARTICLE; BICARBONATE BLOOD LEVEL; BODY MASS; CASE REPORT; CREATININE BLOOD LEVEL; DIABETIC KETOACIDOSIS; DISEASE ASSOCIATION; DRUG WITHDRAWAL; DYSPNEA; ESTHETIC SURGERY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HOSPITAL ADMISSION; HUMAN; INSULIN TREATMENT; INTENSIVE CARE UNIT; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIOPERATIVE PERIOD; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; KETOACIDOSIS; METABOLISM;

ADULT; BLOOD GLUCOSE; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; KETOSIS; LIRAGLUTIDE; METFORMIN; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84990044971 PISSN: 00034819 EISSN: 15393704 Source Type: Journal
DOI: 10.7326/L15-0535 Document Type: Article

Times cited : (8)

References (5)

1
- 84964529459
- Accessed at 17 December 2015.
- U.S. Food and Drug Administration. FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Accessed at www .fda.gov/Drugs/DrugSafety/ucm475463.htm on 17 December 2015.
- FDA Drug Safety Communication: FDA Revises Labels of SGLT2 Inhibitors for Diabetes to Include Warnings about Too Much Acid in the Blood and Serious Urinary Tract Infections

2
- 84962381148
- Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program
- [PMID: 26203064]
- Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38:1680-6. [PMID: 26203064] doi:10.2337/dc15-1251
- (2015) Diabetes Care , vol.38 , pp. 1680-1686
- Erondu, N.¹ Desai, M.² Ways, K.³ Meininger, G.⁴

3
- 84962339296
- Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition
- [PMID: 26078479]
- Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1687-93. [PMID: 26078479] doi:10.2337/dc15-0843
- (2015) Diabetes Care , vol.38 , pp. 1687-1693
- Peters, A.L.¹ Buschur, E.O.² Buse, J.B.³ Cohan, P.⁴ Diner, J.C.⁵ Hirsch, I.B.⁶

4
- 84937763347
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- [PMID: 25894829]
- Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thé venet J, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512-7. [PMID: 25894829] doi:10.1038/nm.3828
- (2015) Nat Med , vol.21 , pp. 512-517
- Bonner, C.¹ Kerr-Conte, J.² Gmyr, V.³ Queniat, G.⁴ Moerman, E.⁵ Thévenet, J.⁶

5
- 84983393416
- Renal glucose handling in diabetes and SGLT-2 inhibition
- Poudel R. Renal glucose handling in diabetes and SGLT-2 inhibition. Indian J Endocrinol Metab. 2013;17: 588-93.
- (2013) Indian J Endocrinol Metab , vol.17 , pp. 588-593
- Poudel, R.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.